We are live on ! Find out more
VP

venBio Partners Portfolio holdings

AUM $519M
1-Year Est. Return 339.42%
This Fund
S&P 500
This Quarter Est. Return
+42.86%
1 Year Est. Return
+339.42%
3 Year Est. Return
+563.8%
5 Year Est. Return
+1,003.88%
10 Year Est. Return
–
AUM
$216M
AUM Growth
+$39.9M
Cap. Flow
-$4.93M
Cap. Flow %
-2.28%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
–
Reduced
2
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
LYEL icon
Lyell Immunopharma
LYEL
+$3.04M
2
ARTV
Artiva Biotherapeutics
ARTV
+$1.89M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHVS icon
1
Pharvaris
PHVS
$2.47B
$129M 59.53%
4,639,304
– –
ALMS
2
Alumis Inc
ALMS
$1.44B
$45.1M 20.85%
4,619,803
– –
HRMY icon
3
Harmony Biosciences
HRMY
$2.46B
$18.3M 8.46%
489,194
– –
ALXO icon
4
ALX Oncology
ALXO
$278M
$11M 5.07%
9,699,925
– –
LYEL icon
5
Lyell Immunopharma
LYEL
$352M
$10.4M 4.81%
337,697
-135,782
-29% -$3.04M
ARTV
6
Artiva Biotherapeutics
ARTV
$547M
$2.78M 1.29%
648,507
-500,468
-44% -$1.89M

Similar funds

CFA
Churchill Financial Advisors Louisville, Kentucky $519M AUM
CFG
Compton Financial Group Towson, Maryland $519M AUM 14.76% 1-Year Est. Return
MWM
Mindset Wealth Management Indianapolis, Indiana $519M AUM 46.03% 1-Year Est. Return
SWM
Scissortail Wealth Management Tulsa, Oklahoma $520M AUM 21.73% 1-Year Est. Return
WS
Wendel SE Paris $519M AUM 48.2% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
MWC
MBM Wealth Consultants Chesterfield, Missouri $519M AUM 16.88% 1-Year Est. Return
PDIP
Palo Duro Investment Partners Chicago, Illinois $518M AUM 22.62% 1-Year Est. Return

venBio Partners's Q4 2025 Portfolio in Review

As of Q4 2025, venBio Partners held 6 positions worth $216M, up 23% from $176M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q4 2025: portfolio turnover was 0%. venBio Partners opened no new positions and made no exits, leaving the 6-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • venBio Partners's biggest Q4 2025 reduction was Lyell Immunopharma, cutting an estimated $3.04M.
  • venBio Partners's ten largest holdings make up 100% of its $216M portfolio in Q4 2025.
  • venBio Partners opened 0 new positions and closed 0 in Q4 2025.
  • venBio Partners's portfolio value rose 23% quarter-over-quarter to $216M.

Based on venBio Partners's 13F filing for Q4 2025, filed 17 Feb 2026.